Kinetics of viral load and antibody response in relation

Journal of Clinical Investigation
130, 5235-5244
DOI: 10.1172/jci138759

Citation Report

#	Article	IF	Citations
1	SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients. Journal of Clinical Virology, 2020, 131, 104611.	1.6	61
2	Loss of Antiâ€“SARS-CoV-2 Antibodies in Mild Covid-19. New England Journal of Medicine, 2020, 383, 1694-1698.	13.9	81
3	Clinical Evaluation of BD Veritor SARS-CoV-2 Point-of-Care Test Performance Compared to PCR-Based Testing and versus the Sofia 2 SARS Antigen Point-of-Care Test. Journal of Clinical Microbiology, 2020, 59, .	1.8	117
5	Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARSâ€CoVâ€2). Clinical and Translational Immunology, 2020, 9, e1182.	1.7	65
6	SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients. Scientific Reports, 2020, 10, 16561.	1.6	84
7	Longer Duration of SARS-CoV-2 Infection in a Case of Mild COVID-19 With Weak Production of the Specific IgM and IgG Antibodies. Frontiers in Immunology, 2020, 11, 1936.	2.2	11
8	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduction and Targeted Therapy, 2020, 5, 282.	7.1	149
9	Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Clinical Infectious Diseases, 2021, 73, e531-e539.	2.9	177
10	Neutralizing Antibody Production in Asymptomatic and Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19 Patients. Journal of Clinical Medicine, 2020, 9, 2268.	1.0	106
11	A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host. Frontiers in Cellular and Infection Microbiology, 2020, 10, 575404.	1.8	4
12	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. International Immunopharmacology, 2020, 88, 106980.	1.7	31
13	Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years. Science, 2020, 370, 811-818.	6.0	210
14	The kinetics of viral load and antibodies to SARS-CoV-2. Clinical Microbiology and Infection, 2020, 26, 1690.e1-1690.e4.	2.8	47
15	Suboptimal SARS-CoV-2â^'specific CD8 ⁺ T cell response associated with the prominent HLA-A*02:01 phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24384-24391.	3.3	168
16	Virological Characterization of the First 2 COVID-19 Patients Diagnosed in Italy: Phylogenetic Analysis, Virus Shedding Profile From Different Body Sites, and Antibody Response Kinetics. Open Forum Infectious Diseases, 2020, 7, ofaa403.	0.4	17
17	Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy. Clinical Infectious Diseases, 2020, 73, e540-e542.	2.9	5
18	Humoral Responses and Serological Assays in SARS-CoV-2 Infections. Frontiers in Immunology, 2020, 11, 610688.	2.2	190
19	Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Science Immunology, 2020, 5, .	5.6	404

#	Article	IF	Citations
20	First performance report of QIAreachâ„¢ Anti-SARS-CoV-2 Total Test, an innovative nanoparticle fluorescence digital detection platform. Journal of Clinical Virology, 2020, 133, 104681.	1.6	7
21	Diagnostic accuracy of serological tests and kinetics of severe acute respiratory syndrome coronavirus 2 antibody: A systematic review and metaâ€analysis. Reviews in Medical Virology, 2021, 31, e2181.	3.9	57
22	Fully automated dried blood spot sample handling and extraction for serological testing of SARSâ€CoVâ€2 antibodies. Drug Testing and Analysis, 2021, 13, 223-226.	1.6	19
23	COVIDâ€19 cutaneous manifestations: simplifying the confusion. International Journal of Dermatology, 2021, 60, 3-4.	0.5	4
24	Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature. Infection Control and Hospital Epidemiology, 2021, 42, 659-668.	1.0	87
25	Risk factors for severe and critically ill COVIDâ€19 patients: A review. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 428-455.	2.7	904
26	Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. Nature Microbiology, 2021, 6, 51-58.	5.9	113
27	Dosing Considerations for Antibodies Against COVID-19. Drugs in R and D, 2021, 21, 1-8.	1.1	5
28	SARS-COV-2 IgG antibody response in pregnant women at delivery. Journal of Gynecology Obstetrics and Human Reproduction, 2021, 50, 102041.	0.6	12
29	Next generation sequencing of SARS-CoV-2 genomes: challenges, applications and opportunities. Briefings in Bioinformatics, 2021, 22, 616-630.	3.2	143
30	Intermittent viral shedding in respiratory samples of patients with SARS-CoV-2: observational analysis with infection control implications. Journal of Hospital Infection, 2021, 107, 98-100.	1.4	17
31	Optimization of hydroxychloroquine dosing scheme based on COVID-19 patientsâ€™ characteristics: a review of the literature and simulations. Xenobiotica, 2021, 51, 127-138.	0.5	6
32	Association of Viral Load in SARS-CoV-2 Patients With Age and Gender. Frontiers in Medicine, 2021, 8, 608215.	1.2	32
33	Immune Response to SARS-CoV-2 Infection in Obesity and T2D: Literature Review. Vaccines, 2021, 9, 102.	2.1	28
34	Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	26
35	Global absence and targeting of protective immune states in severe COVID-19. Nature, 2021, 591, 124-130.	13.7	206
36	Characteristics of COVID-19 Patients Based on the Results of Nucleic Acid and Specific Antibodies and the Clinical Relevance of Antibody Levels. Frontiers in Molecular Biosciences, 2020, 7, 605862.	1.6	4
37	A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cellular and Molecular Immunology, 2021, 18, 318-327.	4.8	270

#	Article	IF	Citations
39	SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Scientific Reports, 2021, 11, 2608.	1.6	86
40	Slip formation of a high-density droplet array for nucleic acid quantification by digital LAMP with a random-access system. Lab on A Chip, 2021, 21, 3086-3093.	3.1	26
41	Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 485-494.	1.3	37
42	SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus. Communications Biology, 2021, 4, 129.	2.0	95
43	Recent biotechnological advances as potential intervention strategies against COVID-19. 3 Biotech, 2021, 11, 41.	1.1	10
44	Effective virus-neutralizing activities in antisera from the first wave of severe COVID-19 survivors. JCI Insight, 2021, 6, .	2.3	10
46	SARS-CoV-2 viral load: Implication in COVID-19 pathogenesis, clinical presentation, diagnosis, treatment, prognosis and infectivity. Journal of Medical Evidence, 2021, .	0.2	0
47	Low-dose ionizing radiation as a hormetin: experimental observations and therapeutic perspective for age-related disorders. Biogerontology, 2021, 22, 145-164.	2.0	29
48	Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19. Heliyon, 2021, 7, e05951.	1.4	15
49	Quantitative Detection of Anti-SARS-CoV-2 Antibodies Using Indirect ELISA. Laboratory Medicine, 2022, 53, 225-234.	0.8	7
51	Analysis of viral load in different specimen types and serum antibody levels of COVID-19 patients. Journal of Translational Medicine, 2021, 19, 30.	1.8	36
52	Treatment of Severe COVID-19 with Convalescent Plasma in Bronx, NYC. JCI Insight, 2021, 6, .	2.3	36
53	Mapping and role of T cell response in SARS-CoV-2â€“infected mice. Journal of Experimental Medicine, 2021, 218, .	4.2	132
54	Seroconversion and Abundance of IgG Antibodies against S1-RBD of SARS-CoV-2 and Neutralizing Activity in the Chilean Population. Journal of Immunology Research, 2021, 2021, 1-11.	0.9	3
55	Another front in COVID-19â€™s perfect storm. Blood, 2021, 137, 1006-1007.	0.6	4
57	Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. RMD Open, 2021, 7, e001549.	1.8	14
58	Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Reports, 2021, 34, 108728.	2.9	568
59	Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests. PLoS ONE, 2021, 16, e0246536.	1.1	17

#	Article	IF	Citations
60	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases, 2021, 80, 698-706.	0.5	37
61	Impaired Cellular Immunity to SARS-CoV-2 in Severe COVID-19 Patients. Frontiers in Immunology, 2021, 12, 603563.	2.2	29
64	Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand. PLoS ONE, 2021, 16, e0246864.	1.1	20
65	Changes in Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Over Time in 10 Sites in the United States, Marchâ€“August, 2020. Clinical Infectious Diseases, 2021, 73, 1831-1839.	2.9	15
66	Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques. Virology, 2021, 554, 97-105.	1.1	30
68	Flow cytometry multiplexed method for the detection of neutralizing human antibodies to the native SARSâ€CoVâ€2 spike protein. EMBO Molecular Medicine, 2021, 13, e13549.	3.3	31
69	Adaptive immunity to SARS-CoV-2 and COVID-19. Cell, 2021, 184, 861-880.	13.5	1,364
70	The intersection of COVID-19 and autoimmunity: What is our current understanding?. Pathogens and Immunity, 2021, 6, 31-54.	1.4	20
72	The conundrum of current anti-SARS-CoV-2 vaccines. Cytokine and Growth Factor Reviews, 2021, 60, 46-51.	3.2	6
75	Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China. Frontiers in Immunology, 2021, 12, 614436.	2.2	17
76	Immune responses to SARS-CoV-2 infection in Humans and ACE2 humanized mice. Fundamental Research, 2021, 1, 124-130.	1.6	5
77	Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. JCI Insight, 2021, 6, .	2.3	29
78	Blockade of SARS-CoV-2 spike protein-mediated cellâ€“cell fusion using COVID-19 convalescent plasma. Scientific Reports, 2021, 11, 5558.	1.6	19
79	Trends of COVID-19 Admissions in an Italian Hub during the Pandemic Peak: Large Retrospective Study Focused on Older Subjects. Journal of Clinical Medicine, 2021, 10, 1115.	1.0	11
80	The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients. Frontiers in Immunology, 2021, 12, 632814.	2.2	62
81	The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic. Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 37-46.	0.2	5
82	Endogenously Produced SARS-CoV-2 Specific IgG Antibodies May Have a Limited Impact on Clearing Nasal Shedding of Virus during Primary Infection in Humans. Viruses, 2021, 13, 516.	1.5	5
83	Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan. Virology, 2021, 555, 35-43.	1.1	31

#	Article	IF	Citations
84	Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalised COVID-19 patients. International Journal of Infectious Diseases, 2021, 104, 661-669.	1.5	18
85	Lessons learned in the collection of convalescent plasma during the COVIDâ€19 pandemic. Vox Sanguinis, 2021, 116, 872-879.	0.7	8
86	Chest pain mimicking pulmonary embolism may be a common presentation of COVIDâ€19 in ambulant patients without other typical features of infection. Journal of Internal Medicine, 2021, 290, 349-358.	2.7	6
87	Antibody kinetics and clinical course of COVID-19 a prospective observational study. PLoS ONE, 2021, 16, e0248918.	1.1	13
88	Sensor Surface Design with NanoMaterials: A New Platform in the Diagnosis of COVID-19. , 0, , .		0
90	COVID-19 convalescent plasma composition and immunological effects in severe patients. Journal of Autoimmunity, 2021, 118, 102598.	3.0	92
91	Persistent neurologic symptoms and cognitive dysfunction in nonâ€hospitalized Covidâ€19 â€œlong haulersâ€. Annals of Clinical and Translational Neurology, 2021, 8, 1073-1085.	1.7	430
92	Distinct kinetics of immunoglobulin isotypes reveal early diagnosis and disease severity of COVIDâ€19: A 6â€month followâ€up. Clinical and Translational Medicine, 2021, 11, e342.	1.7	8
93	Clinical Application of Serologic Testing for Coronavirus Disease 2019 in Contemporary Cardiovascular Practice. Journal of the American Heart Association, 2021, 10, e019506.	1.6	8
94	COVID-19 re-infection: Diagnostic challenges and proposed diagnostic criteria. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 645-648.	1.8	8
95	Antibody response patterns in COVIDâ€19 patients with different levels of disease severity in Japan. Journal of Medical Virology, 2021, 93, 3211-3218.	2.5	52
96	Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. Journal of Experimental Medicine, 2021, 218, .	4.2	259
97	Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities. Scientific Reports, 2021, 11, 5538.	1.6	37
98	A trend of dropping antiâ€SARSâ€CoVâ€2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors. Transfusion, 2021, 61, 1440-1446.	0.8	13
99	Longitudinal Analysis and Comparison of Six Serological Assays up to Eight Months Post-COVID-19 Diagnosis. Journal of Clinical Medicine, 2021, 10, 1815.	1.0	10
100	Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review 31. British Journal of Pharmacology, 2021, 178, 3359-3372.	2.7	10
101	Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. Cell Host and Microbe, 2021, 29, 551-563.e5.	5.1	87
102	Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients. Biosensors and Bioelectronics, 2021, 178, 113008.	5.3	21

#	Article	IF	Citations
103	Longitudinal assessment of IFN-I activity and immune profile in critically ill COVID-19 patients with acute respiratory distress syndrome. Critical Care, 2021, 25, 140.	2.5	27
104	Nature and Duration of Protective Antibodies Developed After COVID-19 Infection. Cocuk Enfeksiyon Dergisi, 2021, 15, 58-61.	0.0	0
105	Disease Severity and Durability of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Response: A View Through the Lens of the Second Year of the Pandemic. Clinical Infectious Diseases, 2021, 73, e1345-e1347.	2.9	3
106	Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019. Clinical Infectious Diseases, 2021, 73, e1337-e1344.	2.9	35
108	Activated CD4+ TÂcells and CD14hiCD16+ monocytes correlate with antibody response following influenza virus infection in humans. Cell Reports Medicine, 2021, 2, 100237.	3.3	4
109	Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. Journal of Clinical Investigation, 2021, 131, .	3.9	58
110	Persistence of SARS-CoV-2 N-Antibody Response in Healthcare Workers, London, UK. Emerging Infectious Diseases, 2021, 27, 1155-1158.	2.0	13
111	Clinical predictors of SARSâ€CoVâ€2 neutralizing antibody titers in COVIDâ€19 convalescents: Implications for convalescent plasma donor recruitment. European Journal of Haematology, 2021, 107, 24-28.	1.1	16
112	Immunoglobulin G Immune Complexes May Contribute to Neutrophil Activation in the Course of Severe Coronavirus Disease 2019. Journal of Infectious Diseases, 2021, 224, 575-585.	1.9	23
113	Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational caseâ€“control study. Journal of Clinical Pathology, 2022, 75, 564-571.	1.0	15
115	Antibody Responses in COVID-19: A Review. Frontiers in Immunology, 2021, 12, 633184.	2.2	105
116	Antibody profile in symptomatic/asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected Saudi persons. Saudi Journal of Biological Sciences, 2021, 28, 4677-4682.	1.8	2
117	Predicting recurrence of respiratory failure in critically ill patients with COVID-19: A preliminary study. Journal of Infection, 2021, 82, e33-e35.	1.7	5
118	Will SARS-CoV-2 Become Just Another Seasonal Coronavirus?. Viruses, 2021, 13, 854.	1.5	11
119	Developing a Paper-Based Antigen Assay to Differentiate between Coronaviruses and SARS-CoV-2 Spike Variants. Analytical Chemistry, 2021, 93, 7825-7832.	3.2	26
120	Practicing With Uncertainty: Kidney Transplantation During the COVID-19 Pandemic. American Journal of Kidney Diseases, 2021, 77, 777-785.	2.1	39
121	Comparison of virus neutralization activity and results of 10 different anti-SARS-CoV-2 serological tests in COVID-19 recovered plasma donors. Practical Laboratory Medicine, 2021, 25, e00222.	0.6	10
123	Longitudinal Serology of SARS-CoV-2-Infected Individuals in India: A Prospective Cohort Study. American Journal of Tropical Medicine and Hygiene, 2021, , .	0.6	18

#	Article	IF	Citations
124	Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study. Signal Transduction and Targeted Therapy, 2021, 6, 197.	7.1	22
125	Evaluation of SARS-CoV-2 Spike S1 Protein Response on PI3K-Mediated IL-8 Release. Medical Sciences (Basel, Switzerland), 2021, 9, 30.	1.3	2
126	COVIDâ€19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts. Immunological Reviews, 2021, 302, 228-240.	2.8	126
127	Potent and Persistent Antibody Response in COVID-19 Recovered Patients. Frontiers in Immunology, 2021, 12, 659041.	2.2	9
128	Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs. Cell Reports, 2021, 35, 109164.	2.9	44
129	Mechanism involved in the pathogenesis and immune response against SARS-CoV-2 infection. VirusDisease, 2021, 32, 211-219.	1.0	6
130	Longevity of Middle East Respiratory Syndrome Coronavirus Antibody Responses in Humans, Saudi Arabia. Emerging Infectious Diseases, 2021, 27, .	2.0	10
132	Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure. JCI Insight, 2021, 6, .	2.3	24
133	Characteristics of coronavirus disease 19 convalescent plasma donors and donations in the New York metropolitan area. Transfusion, 2021, 61, 2374-2383.	0.8	6
134	Is COVID-19 severity associated with anti-spike antibody duration? Data from the ARCOVID prospective observational study. Journal of Infection, 2021, 82, e28-e30.	1.7	5
135	Early Convalescent Plasma Therapy and Mortality Among US Veterans Hospitalized With Nonsevere COVID-19: An Observational Analysis Emulating a Target Trial. Journal of Infectious Diseases, 2021, 224, 967-975.	1.9	14
137	Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19. Journal of Clinical Virology, 2021, 139, 104847.	1.6	37
138	Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset. Frontiers in Immunology, 2021, 12, 708523.	2.2	70
140	Immune characterization of a Colombian family cluster with SARS-CoV-2 infection. Biomedica, 2021, 41, 86-102.	0.3	2
141	The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. PLoS ONE, 2021, 16, e0253487.	1.1	76
142	Relative COVID-19 Viral Persistence and Antibody Kinetics. Pathogens, 2021, 10, 752.	1.2	9
143	Dynamics of host immune responses to SARS-CoV-2. World Journal of Clinical Cases, 2021, 9, 4480-4490.	0.3	0
144	Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India. Indian Journal of Clinical Biochemistry, 2021, 36, 485-491.	0.9	0

#	Article	IF	Citations
145	Usefulness of Sputum and Pharyngeal Swab Specimens for Diagnosis of Coronavirus Disease 2019. Korean Journal of Family Practice, 2021, 11, 164-169.	0.1	0
146	COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. Angiogenesis, 2021, 24, 755-788.	3.7	114
147	COVID-19 convalescent plasma: mechanisms of action and rationale for use: a narrative review. Annals of Blood, 0, 6, 16-16.	0.4	1
148	Methods to Identify Immunogenic Peptides in SARSâ€CoVâ€2 Spike and Protective Monoclonal Antibodies in COVIDâ€19 Patients. Small Methods, 2021, 5, 2100058.	4.6	6
149	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Frontiers in Medicine, 2021, 8, 684151.	1.2	50
151	Fatal cytomegalovirus pneumonia in a critically ill patient with COVID â€19. Respirology Case Reports, 2021, 9, e00801.	0.3	15
152	A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States. EClinicalMedicine, 2021, 36, 100902.	3.2	85
153	Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2. ImmunoHorizons, 2021, 5, 466-476.	0.8	23
154	Immune responses and therapeutic challenges in paediatric patients with newâ€onset acute myeloid leukaemia and concomitant COVIDâ€19. British Journal of Haematology, 2021, 194, 549-553.	1.2	5
155	Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India. Virology, 2021, 558, 13-21.	1.1	24
156	Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assayâ€“Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation With Immunoglobulin G Commercial Serology Assays. Archives of Pathology and Laboratory Medicine, 2021, 145, 1212-1220.	1.2	38
158	Extracorporal hemocorrection methods for COVID-19: are there outlooks?. Nephrology (Saint-Petersburg), 2021, 25, 95-106.	0.1	0
159	SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain. Journal of Immunology, 2021, 207, 878-887.	0.4	30
160	Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. Journal of Clinical Investigation, 2021, 131, .	3.9	170
161	Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia. Journal of Infection and Public Health, 2021, 14, 832-838.	1.9	27
162	A Quantitative ELISA Protocol for Detection of Specific Human IgG against the SARS-CoV-2 Spike Protein. Vaccines, 2021, 9, 770.	2.1	8
163	Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. PLoS ONE, 2021, 16, e0253977.	1.1	35
165	Seroprevalence of SARS-CoV-2 Binding and Neutralizing Antibodies in Healthcare Workers during the Epidemic Peak in Referral Hospitals and Quarantine Sites: Saudi Arabia. Viruses, 2021, 13, 1413.	1.5	16

#	Article	IF	Citations
166	Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVIDâ€19: A case study. Journal of Medical Virology, 2021, 93, 5947-5952.	2.5	64
167	SARS-CoV-2 Infection and Antibody-Dependent Enhancement. Studies in Computational Intelligence, 2022, , 101-113.	0.7	0
168	The Impact of SARS-CoV-2 Viral Load on the Mortality of Hospitalized Patients: A Retrospective Analysis. Cureus, 2021, 13, e16540.	0.2	1
170	Clinical and immunological features of new coronaviral infection SARS-COV-2 in pregnant women (review). Bulletin Physiology and Pathology of Respiration, 2021, , 91-99.	0.0	2
171	Insights into the virologic and immunologic features of SARS-COV-2. World Journal of Clinical Cases, 2021, 9, 5007-5018.	0.3	3
172	Profiles of SARS-CoV-2 RNA and Antibodies in Inpatients with COVID-19 not Related with Clinical Manifestation: A Single Centre Study. Virologica Sinica, 2021, 36, 1088-1092.	1.2	0
173	SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes. Journal of Clinical Investigation, 2021, 131, .	3.9	94
174	Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19. Frontiers in Pharmacology, 2021, 12, 709856.	1.6	23
175	SARS-CoV-2 (COVID-19), viral load and clinical outcomes; lessons learned one year into the pandemic: A systematic review. World Journal of Critical Care Medicine, 2021, 10, 132-150.	0.8	50
176	Seroconversion among COVID-19 patients admitted in a dedicated COVID hospital: A longitudinal prospective study of 1000 patients. Medical Journal Armed Forces India, 2021, 77, S379-S384.	0.3	12
177	Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2021, 15, e0009551.	1.3	25
178	Long-Term Persistence and Relevant Therapeutic Impact of High-Titer Viral-Neutralizing Antibody in a Convalescent COVID-19 Plasma Super-Donor: A Case Report. Frontiers in Immunology, 2021, 12, 690322.	2.2	0
179	Risk factors and predictors that influence SARS-Cov-2 IgG positivity. Journal of King Abdulaziz University, Islamic Economics, 2021, 42, 853-861.	0.5	2
180	Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineate immune responses in patients with COVID-19. Science Immunology, 2021, 6, .	5.6	108
181	Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients. Frontiers in Immunology, 2021, 12, 723585.	2.2	11
182	Immunity to SARSâ€CoVâ€2 induced by infection or vaccination. Journal of Internal Medicine, 2022, 291, 32-50.	2.7	97
183	Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges. Frontiers in Microbiology, 2021, 12, 637554.	1.5	8
184	Mouth Washing Impaired SARS-CoV-2 Detection in Saliva. Diagnostics, 2021, 11, 1509.	1.3	5

#	Article	IF	Citations
185	Detection of Anti-SARS-CoV-2-S2 IgG Is More Sensitive Than Anti-RBD IgG in Identifying Asymptomatic COVID-19 Patients. Frontiers in Immunology, 2021, 12, 724763.	2.2	14
187	Applications of laboratory findings in the prevention, diagnosis, treatment, and monitoring of COVID-19. Signal Transduction and Targeted Therapy, 2021, 6, 316.	7.1	17
189	Multicentre Performance Evaluation of the Elecsys Anti-SARS-CoV-2 Immunoassay as an Aid in Determining Previous Exposure to SARS-CoV-2. Infectious Diseases and Therapy, 2021, 10, 2381-2397.	1.8	14
190	Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study. Science Immunology, 2021, 6, .	5.6	20
191	Seroprevalence of SARS-CoV-2 antibodies, associated epidemiological factors and antibody kinetics among healthcare workers in Connecticut. Journal of Hospital Infection, 2021, 114, 117-125.	1.4	8
192	Serological surveys to estimate cumulative incidence of SARS-CoV-2 infection in adults (Sero-MAss) Tj ETQq1 1 0.784314 rgBT /Overl	0.8	7
193	SARS-CoV-2 Antibody Testing: Where Are We Now?. Laboratory Medicine, 2021, , .	0.8	2
194	Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Military Medical Research, 2021, 8, 47.	1.9	88
195	Sustained seroprevalence of SARS-CoV-2 antibodies one year after infection: one of the first COVID-19 cluster cases in Bosnia and Herzegovina. Bosnian Journal of Basic Medical Sciences, 2021, , .	0.6	4
196	Comparison of SARS-CoV-2- and HCoV-Specific T Cell Response Using IFN-Î³ ELISpot. Diagnostics, 2021, 11, 1439.	1.3	6
198	Serological and viral genetic features of patients with COVID-19 in a selected German patient cohortâ€"correlation with disease characteristics. GeroScience, 2021, 43, 2249-2264.	2.1	4
199	Seasonal coronavirusâ€"specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19. Journal of Clinical Investigation, 2021, 131, .	3.9	49
200	Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVIDâ€19 infection: Prospective observational study. Journal of Medical Virology, 2022, 94, 279-286.	2.5	20
201	Enhanced eosinophil-mediated inflammation associated with antibody and complement-dependent pneumonic insults in critical COVID-19. Cell Reports, 2021, 37, 109798.	2.9	28
203	Immune Responses against SARS-CoV-2â€"Questions and Experiences. Biomedicines, 2021, 9, 1342.	1.4	10
204	Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. Science Immunology, 2021, 6, eabj2901.	5.6	67
205	Gut Microbiome Alterations in COVID-19. Genomics, Proteomics and Bioinformatics, 2021, 19, 679-688.	3.0	62
206	Longitudinal Analysis of Inflammatory Response to SARS-CoV-2 in the Upper Respiratory Tract Reveals an Association with Viral Load, Independent of Symptoms. Journal of Clinical Immunology, 2021, 41, 1723-1732.	2.0	7

#	Article	IF	Citations
207	Multiepitope Proteins for the Differential Detection of IgG Antibodies against RBD of the Spike Protein and Non-RBD Regions of SARS-CoV-2. Vaccines, 2021, 9, 986.	2.1	8
208	SARS-CoV-2-specific T cells in infection and vaccination. Cellular and Molecular Immunology, 2021, 18, 2307-2312.	4.8	131
209	Possibility of deterioration of respiratory status when steroids precede antiviral drugs in patients with COVID-19 pneumonia: A retrospective study. PLoS ONE, 2021, 16, e0256977.	1.1	14
212	Cross-reactive humoral immune responses against seasonal human coronaviruses in COVID-19 patients with different disease severities. International Journal of Infectious Diseases, 2021, 111, 68-75.	1.5	9
214	Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay. Journal of Virological Methods, 2021, 297, 114271.	1.0	88
215	Efficient COVID-19 testing via contextual model based compressive sensing. Pattern Recognition, 2022, 122, 108253.	5.1	0
216	The Neutralizing Antibody Response against Severe Acute Respiratory Syndrome Coronavirus 2 and the Cytokine/Chemokine Release in Patients with Different Levels of Coronavirus Diseases 2019 Severity: Cytokine Storm Still Persists Despite Viral Disappearance in Critical Patients. JMA Journal, 2021, 4, 1-7.	0.6	5
218	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. SSRN Electronic Journal, 0, , .	0.4	2
219	Comprehensive analysis of COVID-19 during pregnancy. Biochemical and Biophysical Research Communications, 2021, 538, 180-186.	1.0	67
220	SARS-CoV-2 Seroconversion and Viral Clearance in Patients Hospitalized With COVID-19: Viral Load Predicts Antibody Response. Open Forum Infectious Diseases, 2021, 8, ofab005.	0.4	52
221	COVID-19 Repeated Convalescent Plasma Collection: Analysis of 149 Donations from 88 French Military Health Workers. Transfusion Medicine and Hemotherapy, 2021, 48, 284-289.	0.7	0
222	Single Extracellular Vesicles (EV) Proteomic Profiling Altered and Identifies Co-Localization of SARS-CoV-2 Nucleocapsid Protein with CD81/Integrin-Rich EV Subpopulation in Sputum Samples of COVID-19 Patients. SSRN Electronic Journal, 0, , .	0.4	0
223	SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses. Epidemiology and Infection, 2021, 149, e153.	1.0	0
224	Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization. Pathogens, 2021, 10, 138.	1.2	60
225	Neutralizing antibody titres in SARS-CoV-2 infections. Nature Communications, 2021, 12, 63.	5.8	303
226	Salivette, a relevant saliva sampling device for SARS-CoV-2 detection. Journal of Oral Microbiology, 2021, 13, 1920226.	1.2	26
227	The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. Oxford Open Immunology, 2021, 2, .	1.2	59
228	Natural history of COVID-19 and therapeutic options. Expert Review of Clinical Immunology, 2020, 16, 1159-1184.	1.3	101

#	Article	IF	Citations
229	Old friends meet a new foe. Evolution, Medicine and Public Health, 2020, 2020, 234-248.	1.1	31
230	Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic. Journal of Infectious Diseases, 2021, 223, 981-984.	1.9	62
231	SARS-CoV-2 Viral Load on Admission Is Associated With 30-Day Mortality. Open Forum Infectious Diseases, 2020, 7, ofaa535.	0.4	31
232	Adaptation of advanced clinical virology assays from HIV-1 to SARS-CoV-2. Current Opinion in HIV and AIDS, 2021, 16, 3-10.	1.5	2
233	Diagnostic testing for SARS-CoV-2/COVID19. Current Opinion in Pediatrics, 2021, 33, 122-128.	1.0	18
256	Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors. JCI Insight, 2020, 5, .	2.3	86
257	SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy. Journal of Clinical Investigation, 2020, 130, 5112-5114.	3.9	56
258	Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals. Journal of Clinical Investigation, 2020, 130, 6588-6599.	3.9	128
259	Does common cold coronavirus infection protect against severe SARS-CoV-2 disease?. Journal of Clinical Investigation, 2021, 131, .	3.9	25
260	COVID-19 update: the first 6 months of the pandemic. Human Genomics, 2020, 14, 48.	1.4	30
261	A rapid review and meta-analysis of the asymptomatic proportion of PCR-confirmed SARS-CoV-2 infections in community settings. Wellcome Open Research, 0, 5, 266.	0.9	24
262	Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis. PLoS ONE, 2020, 15, e0241164.	1.1	47
265	Factors of Severity in Patients with COVID-19: Cytokine/Chemokine Concentrations, Viral Load, and Antibody Responses. American Journal of Tropical Medicine and Hygiene, 2020, 103, 2412-2418.	0.6	60
266	Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel. Seminars in Immunology, 2021, 55, 101507.	2.7	16
267	Kinetics of Neutralizing Antibody Response Underscores Clinical COVID-19 Progression. Journal of Immunology Research, 2021, 2021, 1-11.	0.9	4
268	Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects. Cellular and Molecular Immunology, 2022, 19, 150-157.	4.8	43
269	Seroprevalence of SARS-CoV-2 in Croatian solid-organ transplant recipients. Biochemia Medica, 2021, 31, 487-493.	1.2	1
270	Agreement between two diagnostic methods for COVID-19: preliminary data from a Brazilian clinical laboratory. Romanian Journal of Laboratory Medicine, 2021, 29, 413-420.	0.1	0

#	Article	IF	Citations
271	Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects. International Immunopharmacology, 2021, 101, 108215.	1.7	20
274	Longitudinal humoral antibody response to SARS-CoV-2 infection among healthcare workers in a New York City hospital. BMJ Open, 2021, 11, e051045.	0.8	6
275	A renewable resource model of health decision-making: insights to improve health marketing. AMS Review, 0, , 1.	1.1	0
276	SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation. Frontiers in Immunology, 2021, 12, 767981.	2.2	36
277	Narrative review of the novel coronavirus SARS-CoV-2: update on genomic characteristics, transmissions and animal model. Journal of Thoracic Disease, 2020, 12, 7454-7466.	0.6	1
278	Performance Characteristics of High-Throughput Serologic Assays for Severe Acute Respiratory Syndrome Coronavirus 2 with Food and Drug Administration Emergency Use Authorization. Clinics in Laboratory Medicine, 2022, 42, 15-29.	0.7	8
280	Gut microbiome, Vitamin D, ACE2 interactions are critical factors in immune-senescence and inflammaging: key for vaccine response and severity of COVID-19 infection. Inflammation Research, 2022, 71, 13-26.	1.6	10
284	Antibody indexes in COVID-19 convalescent plasma donors: Unanswered questions. Clinics, 2021, 76, e2818.	0.6	2
285	Overview of the immune response against SARS-CoV-2. , 2022, , 95-113.		0
287	Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses â€" are we our own worst enemy?. Nature Reviews Immunology, 2022, 22, 47-56.	10.6	118
288	SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma. Microbiology Spectrum, 2021, 9, e0139721.	1.2	15
289	Immunological Biomarkers in Blood to Monitor the Course and Therapeutic Outcomes of COVID-19. Therapeutic Drug Monitoring, 2021, Publish Ahead of Print, .	1.0	1
290	Whole bloodâ€based measurement of SARSâ€CoVâ€2â€specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solidâ€organ cancers. Immunology, 2022, 165, 250-259.	2.0	21
291	Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities. Frontiers in Microbiology, 2021, 12, 789374.	1.5	7
292	SARSâ€CoVâ€2 during pregnancy and associated outcomes: Results from an ongoing prospective cohort. Paediatric and Perinatal Epidemiology, 2022, 36, 466-475.	0.8	17
293	Duration of SARS-CoV-2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID-19: a cohort study. Diagnostic Microbiology and Infectious Disease, 2022, 102, 115595.	0.8	28
294	Kidney Transplant Recipient Behavior During the Early COVID-19 Pandemic: A National Survey Study in Norway. Kidney Medicine, 2022, 4, 100389.	1.0	2
295	Immunoglobulin (Ig)A seropositivity against SARS-CoV-2 in healthcare workers in Israel, 4 April to 13 July 2020: an observational study. Eurosurveillance, 2021, 26, .	3.9	0

#	Article	IF	Citations
298	Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2. EBioMedicine, 2021, 74, 103700.	2.7	37
299	The host immune responses to SARS-CoV-2 and therapeutic strategies in the treatment of COVID-19 cytokine storm. AIMS Allergy and Immunology, 2021, 5, 240-258.	0.3	1
300	Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers. International Immunopharmacology, 2022, 103, 108491.	1.7	17
301	Immune responses to human respiratory coronaviruses infection in mouse models. Current Opinion in Virology, 2022, 52, 102-111.	2.6	5
302	Single-cell immunology of SARS-CoV-2 infection. Nature Biotechnology, 2022, 40, 30-41.	9.4	78
303	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Research, 2022, 32, 269-287.	5.7	54
304	The effectiveness of the immune responses to SARS-CoV-2. , 2022, Publish Ahead of Print, .		0
307	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. Pharmacological Reviews, 2022, 74, 313-339.	7.1	9
308	Nine-month course of SARS-CoV-2 antibodies in individuals with COVID-19 infection. Irish Journal of Medical Science, 2022, 191, 2803-2811.	0.8	6
309	Evaluation of serological anti-SARS-CoV-2 chemiluminescent immunoassays correlated to live virus neutralization test, for the detection of anti-RBD antibodies as a relevant alternative in COVID-19 large-scale neutralizing activity monitoring. Clinical Immunology, 2022, 234, 108918.	1.4	15
310	Evaluation of Rapid Antigen Tests Using Nasal Samples to Diagnose SARS-CoV-2 in Symptomatic Patients. Frontiers in Public Health, 2021, 9, 728969.	1.3	10
311	Serological evaluation of patients with coronavirus disease-2019 in Daegu, South Korea. PLoS ONE, 2022, 17, e0262820.	1.1	1
312	Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition. Frontiers in Immunology, 2022, 13, 830710.	2.2	19
313	Measurement of SARS-CoV-2 Antibody Titers Improves the Prediction Accuracy of COVID-19 Maximum Severity by Machine Learning in Non-Vaccinated Patients. Frontiers in Immunology, 2022, 13, 811952.	2.2	9
316	Innovative FO-SPR Label-free Strategy for Detecting Anti-RBD Antibodies in COVID-19 Patient Serum and Whole Blood. ACS Sensors, 2022, 7, 477-487.	4.0	31
317	A systematic review and meta-analysis of the sensitivity of antibody tests for the laboratory confirmation of COVID-19. Future Virology, 2022, 17, 119-139.	0.9	18
318	SARS-CoV-2 RT-PCR positivity of individuals subsequent to completing quarantine upon entry into a country during a transmission-free period. Travel Medicine and Infectious Disease, 2022, 46, 102271.	1.5	4
319	Fear of Corona and Depression in Graduate Students; Mediating Role of Stress and Anxiety.. Journal of Research in Psychology, 2021, 3, 72-84.	0.4	0

#	Article	IF	Citations
320	Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection. Scientific Reports, 2022, 12, 2077.	1.6	8
321	Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nature Microbiology, 2022, 7, 423-433.	5.9	78
323	Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination. PLoS Pathogens, 2021, 17, e1010211.	2.1	37
324	Activation of Sphingomyelinase-Ceramide-Pathway in COVID-19 Purposes Its Inhibition for Therapeutic Strategies. Frontiers in Immunology, 2021, 12, 784989.	2.2	15
326	Probabilistic classification of antiâ€SARSâ€CoVâ€2 antibody responses improves seroprevalence estimates. Clinical and Translational Immunology, 2022, 11, e1379.	1.7	4
328	Biomarker identification using dynamic time warping analysis: a longitudinal cohort study of patients with COVID-19 in a UK tertiary hospital. BMJ Open, 2022, 12, e050331.	0.8	10
329	A method comparison of three immunoassays for detection of neutralizing antibodies against SARSâ€CoVâ€2 receptorâ€binding domain in individuals with adenovirus typeâ€5â€vectored COVIDâ€19 vaccination. Journal of Clinical Laboratory Analysis, 2022, 36, e24306.	0.9	2
330	Characterization of the antibody response to SARSâ€CoVâ€2 in a mildly affected pediatric population. Pediatric Allergy and Immunology, 2022, 33, e13737.	1.1	5
331	Use of Early Donated COVID-19 Convalescent Plasma Is Optimal to Preserve the Integrity of Lymphatic Endothelial Cells. Pharmaceuticals, 2022, 15, 365.	1.7	2
332	Seroprevalence of SARS-Cov-2 IgG antibodies in patients at a single center in Saudi Arabia. Annals of Saudi Medicine, 2022, 42, 69-74.	0.5	0
333	SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests. Scientific Reports, 2022, 12, 3351.	1.6	0
334	Self-administered, remote assessment of SARS-CoV-2 seroprevalence in health care workers. American Journal of the Medical Sciences, 2022, 364, 281-288.	0.4	0
336	Evaluation of Spike Protein Epitopes by Assessing the Dynamics of Humoral Immune Responses in Moderate COVID-19. Frontiers in Immunology, 2022, 13, 770982.	2.2	4
337	Multiscale Model of Antiviral Timing, Potency, and Heterogeneity Effects on an Epithelial Tissue Patch Infected by SARS-CoV-2. Viruses, 2022, 14, 605.	1.5	8
338	Interleukin-6-Production Is Responsible for Induction of Hepatic Synthesis of Several Chemokines as Acute-Phase Mediators in Two Animal Models: Possible Significance for Interpretation of Laboratory Changes in Severely Ill Patients. Biology, 2022, 11, 470.	1.3	1
339	Characteristics of natural immunity to SARS-CoV-2 over time in wait-listed dialysis patients and recent kidney transplant recipients. Nephrology Dialysis Transplantation, 2022, , .	0.4	1
341	NETosis and SARS-COV-2 infection related thrombosis: a narrative review. Thrombosis Journal, 2022, 20, 13.	0.9	20
342	Neutralizing Antibodies and Cellular Immune Responses Against SARS-CoV-2 Sustained One and a Half Years After Natural Infection. Frontiers in Microbiology, 2021, 12, 803031.	1.5	18

#	Article	IF	Citations
343	The interplay of viral loads, clinical presentation, and serological responses in SARS-CoV-2 â€“ Results from a prospective cohort of outpatient COVID-19 cases. Virology, 2022, 569, 37-43.	1.1	9
344	Anti-SARS-CoV-2 IgG and Neutralizing Antibody Levels in Patients with Past COVID-19 Infection: A Longitudinal Study. Balkan Medical Journal, 2022, , .	0.3	6
345	INVESTIGATION AND LONGâ€TERM MONITORING OF THE PRESENCE OF NEUTRALIZING ANTIBODY IN PATIENTS WITH COVIDâ€19 DISEASE OF DIFFERENT CLINICAL SEVERITY. Journal of Medical Virology, 2022, , .	2.5	5
346	Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19. Frontiers in Immunology, 2021, 12, 798276.	2.2	3
347	Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. PLoS Medicine, 2021, 18, e1003868.	3.9	20
348	Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS-CoV-2 Natural Infection. Vaccines, 2021, 9, 1499.	2.1	43
349	Protective Immunity against Gamma and Zeta Variants after Inactivated SARS-CoV-2 Virus Immunization. Viruses, 2021, 13, 2440.	1.5	8
350	Erythrocytes increase endogenous sphingosine 1-phosphate levels as an adaptive response to SARS-CoV-2 infection. Clinical Science, 2021, 135, 2781-2791.	1.8	11
351	IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients. BMC Microbiology, 2021, 21, 351.	1.3	13
352	The relationship between COVIDâ€19 viral load and disease severity: A systematic review. Immunity, Inflammation and Disease, 2022, 10, .	1.3	86
353	Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study. Infection and Drug Resistance, 2021, Volume 14, 5287-5291.	1.1	9
354	Why Does the Severity of COVID-19 Differ With Age?. Pediatric Infectious Disease Journal, 2022, 41, e36-e45.	1.1	49
355	Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination. Clinical Gastroenterology and Hepatology, 2022, 20, e1493-e1499.	2.4	15
356	Detection and predictors of anti-SARS-CoV-2 antibody levels in COVID-19 patients at 8Âmonths after symptom onset. Future Virology, 2021, 16, 795-804.	0.9	6
357	Overlapping but Disparate Inflammatory and Immunosuppressive Responses to SARS-CoV-2 and Bacterial Sepsis: An Immunological Time Course Analysis. Frontiers in Immunology, 2021, 12, 792448.	2.2	18
359	Antibody Profiling in COVID-19 Patients with Different Severities by Using Spike Variant Protein Microarrays. Analytical Chemistry, 2022, , .	3.2	7
360	Observations and perspectives on adaptive immunity to SARS-CoV-2. Clinical Infectious Diseases, 2022, , .	2.9	10
361	BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19. Frontiers in Immunology, 2022, 13, 797918.	2.2	1

#	Article	IF	Citations
362	Antibody and T Cell Immune Responses to SARS-CoV-2 Peptides in COVID-19 Convalescent Patients. Frontiers in Microbiology, 2022, 13, 842232.	1.5	4
363	SARS-CoV-2 IgM testing for travellers: a private pathology perspective from New South Wales and the Australian Capital Territory, Australia. Pathology, 2022, , .	0.3	0
365	Influential factor and trend of specific IgG antibody titer in coronavirus disease 2019 convalescents. Journal of Central South University (Medical Sciences), 2020, 45, 1172-1175.	0.1	1
366	Kinetic Characteristics of Neutralizing Antibody Responses Vary among Patients with COVID-19.. Biomedical and Environmental Sciences, 2021, 34, 976-983.	0.2	1
367	Memory CD4+ T-Cell Lymphocytic Angiopathy in Fatal Forms of COVID-19 Pulmonary Infection. Frontiers in Immunology, 2022, 13, 844727.	2.2	2
368	Structural mapping of antibody landscapes to human betacoronavirus spike proteins. Science Advances, 2022, 8, eabn2911.	4.7	28
369	Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine, 2022, 47, 101409.	3.2	20
370	IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes. Cell Reports, 2022, 39, 110904.	2.9	9
371	SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity. Nature Communications, 2022, 13, 2774.	5.8	21
372	Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: An updated systematic review and meta-analysis with meta-regression analyzing influencing factors. PLoS Medicine, 2022, 19, e1004011.	3.9	35
373	COVID-19 hastalarÄ±nÄ±n semptomlarÄ±na ve pnÃ¶moni varlÄ±ÄŸÄ±na gÃ¶re antikor tepkileri. Family Practice and Palliative Care, 0, , 36-40.	0.2	0
374	Two-year seroprevalence surveys of SARS-CoV-2 antibodies among outpatients and healthcare workers in Japan. Japanese Journal of Infectious Diseases, 2022, , .	0.5	2
375	Clinical Characteristics of Immune Response in Asymptomatic Carriers and Symptomatic Patients With COVID-19. Frontiers in Microbiology, 2022, 13, .	1.5	0
376	Evolution of neurologic symptoms in nonâ€hospitalized <scp>COVID</scp>â€19 â€œlong haulersâ€• Annals of Clinical and Translational Neurology, 2022, 9, 950-961.	1.7	42
377	SARS-CoV-2 RNA copy number is a factor associated with the mortality of COVID-19 and improves the predictive performance of mortality in severe cases.. Japanese Journal of Infectious Diseases, 2022, , .	0.5	0
378	Low SARS-CoV-2 antibody titers may be associated with poor clinical outcomes for patients with severe COVID-19. Scientific Reports, 2022, 12, .	1.6	12
379	Correlates of protection against <scp>SARS</scp>â€<scp>CoV</scp>â€2 infection and COVIDâ€19 disease. Immunological Reviews, 2022, 310, 6-26.	2.8	138
380	The humoral immune response more than one year after SARS-CoV-2 infection: low detection rate of anti-nucleocapsid antibodies via Euroimmun ELISA. Infection, 2023, 51, 83-90.	2.3	7

#	Article	IF	Citations
381	Duration of SARS-CoV-2 RNA positivity from various specimens and clinical characteristics in patients with COVID-19: a systematic review and meta-analysis. Inflammation and Regeneration, 2022, 42, .	1.5	7
382	Predictors of COVID-19 severity and hospitalization: A survey-based study from Jordan. Informatics in Medicine Unlocked, 2022, 31, 100994.	1.9	2
383	Do the Kinetics of Antibody Responses Predict Clinical Outcome in Hospitalized Patients With Moderate-to-Severe COVID-19?. In Vivo, 2022, 36, 1944-1948.	0.6	1
385	Antibodies against SARS-CoV-2 after natural infection in healthcare workers and clinical characteristics as putative antibody production prediction. Journal of Clinical Virology Plus, 2022, , 100089.	0.4	0
386	Serologic Tests for COVID-19 Infections and Vaccination. Pediatric Infectious Disease Journal, 2022, 41, e304-e305.	1.1	0
387	Impaired Antibody Response Is Associated with Histone-Release, Organ Dysfunction and Mortality in Critically Ill COVID-19 Patients. Journal of Clinical Medicine, 2022, 11, 3419.	1.0	1
388	Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors. Frontiers in Immunology, 0, 13, .	2.2	10
389	COVID-19 Clinical Severity, T Cell-Mediated Immune Response, and Correlates of Inflammation: Not an Intuitive Guess. SSRN Electronic Journal, 0, , .	0.4	0
390	Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds. Microbiology Spectrum, 2022, 10, .	1.2	7
391	Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer. PLoS ONE, 2022, 17, e0271066.	1.1	17
392	SARS-CoV-2-Induced Immunosuppression: A Molecular Mimicry Syndrome. Global Medical Genetics, 2022, 09, 191-199.	0.4	3
393	Antibody levels to <scp>SARSâ€CoV</scp>â€2 spike protein in mothers and children from delivery to six months later. Birth, 2023, 50, 418-427.	1.1	5
394	Prevalence of anti-SARS-CoV-2 antibodies and associated factors in healthcare workers of a Mexican Covid-19 hospital. Salud Publica De Mexico, 2022, 64, 348-356.	0.1	1
395	Neutralizing antibodies and cellular immune response after two doses of inactivated SARS-CoV-2 vaccine in China. Expert Review of Vaccines, 2022, 21, 1465-1473.	2.0	3
396	Human IgG antibody responses to severe acute respiratory syndrome coronavirus 2 viral antigens receptor-binding domain, spike, and nucleocapsid, in vaccinated adults from Merida, Mexico. Frontiers in Medicine, 0, 9, .	1.2	0
397	SARS-CoV-2 S2â€"targeted vaccination elicits broadly neutralizing antibodies. Science Translational Medicine, 2022, 14, .	5.8	57
399	High Seroprevalence of SARS-CoV-2 IgG and RNA among Asymptomatic Blood Donors in Makkah Region, Saudi Arabia. Vaccines, 2022, 10, 1279.	2.1	1
400	Dysregulation of immunity in COVID-19 and SLE. Inflammopharmacology, 2022, 30, 1517-1531.	1.9	6

#	Article	IF	Citations
401	The striking mimics between COVID-19 and malaria: A review. Frontiers in Immunology, 0, 13, .	2.2	9
402	SARS-CoV-2 viral load in the upper respiratory tract and disease severity in COVID-19 patients. World Journal of Meta-analysis, 2022, 10, 195-205.	0.1	0
403	Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. Nature Communications, 2022, 13, .	5.8	12
404	Ultrarapid and ultrasensitive detection of SARSâ€CoVâ€2 antibodies in COVIDâ€19 patients via a 3Dâ€printed nanomaterialâ€based biosensing platform. Journal of Medical Virology, 2022, 94, 5808-5826.	2.5	8
405	SARS-CoV-2 immunity and vaccine strategies in people with HIV. Oxford Open Immunology, 2022, 3, .	1.2	12
406	Act Early and at the Right Location: SARS-CoV-2 T Cell Kinetics and Tissue Localization. International Journal of Molecular Sciences, 2022, 23, 10679.	1.8	5
407	Biotechnological Strategies in the Intervention and Treatment of COVID-19. , 2022, , 421-442.		1
408	Early COVID-19 respiratory risk stratification using machine learning. Trauma Surgery and Acute Care Open, 2022, 7, e000892.	0.8	0
409	Low quantity and quality of anti-spike humoral response is linked to CD4 T-cell apoptosis in COVID-19 patients. Cell Death and Disease, 2022, 13, .	2.7	5
410	New Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge?. Vaccines, 2022, 10, 1607.	2.1	5
411	Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies. Scientific Reports, 2022, 12, .	1.6	8
412	COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine. PLoS ONE, 2022, 17, e0273323.	1.1	3
413	Delineating the SARS-CoV-2 Induced Interplay between the Host Immune System and the DNA Damage Response Network. Vaccines, 2022, 10, 1764.	2.1	4
414	Early SARS-CoV-2 dynamics and immune responses in unvaccinated participants of an intensely sampled longitudinal surveillance study. Communications Medicine, 2022, 2, .	1.9	1
415	Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant. JCI Insight, 2022, 7, .	2.3	14
416	Antibody Dependent Enhancement of SARS-CoV-2 Infection in the Era of Rapid Vaccine Development. Medicinski Arhiv = Medical Archives = Archives De MÃ©decine, 2022, 76, 383.	0.4	1
417	Buffy Coat Transcriptomic Analysis Reveals Alterations in Host Cell Protein Synthesis and Cell Cycle in Severe COVID-19 Patients. International Journal of Molecular Sciences, 2022, 23, 13588.	1.8	7
418	Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients. Scientific Reports, 2022, 12, .	1.6	9

#	Article	IF	Citations
419	A Four-Channel Surface Plasmon Resonance Sensor Functionalized Online for Simultaneous Detections of Anti-SARS-CoV-2 Antibody, Free Viral Particles, and Neutralized Viral Particles. ACS Sensors, 2022, 7, 3560-3570.	4.0	5
420	Determining the SARS-CoV-2 Anti-Spike Cutoff Level Denoting Neutralizing Activity Using Two Commercial Kits. Vaccines, 2022, 10, 1952.	2.1	3
421	Changing Features of Liver Injury in COVID-19 Patients: Impact of Infection with the SARS-CoV-2 Delta (B.1.617.2) Variants. Infection and Chemotherapy, 2022, 54, 744.	1.0	2
422	CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses. Viruses, 2022, 14, 2665.	1.5	2
423	The dynamics and determinants of specific systemic and mucosal antibody responses to SARS-CoV-2 in three adult cohorts in the Ecuadorian Andes: a study protocol. F1000Research, 0, 11, 1392.	0.8	0
424	Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination. Emerging Microbes and Infections, 2023, 12, .	3.0	13
425	Community-Based Seroprevelance of SARS-CoV-2 in Saudi Arabia. Cureus, 2022, , .	0.2	0
426	Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nature Reviews Immunology, 2023, 23, 381-396.	10.6	61
427	Association between immunity and viral shedding duration in non-severe SARS-CoV-2 Omicron variant-infected patients. Frontiers in Public Health, 0, 10, .	1.3	1
428	Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes. Vaccines, 2022, 10, 2063.	2.1	1
429	Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization. IScience, 2023, 26, 105969.	1.9	6
430	Correlation of ENT Symptoms with Age, Sex, and Anti-SARS-CoV-2 Antibody Titer in Plasma. Journal of Clinical Medicine, 2023, 12, 610.	1.0	2
431	Mathematical Modeling and Analysis of the Dynamics of RNA Viruses in Presence of Immunity and Treatment: A Case Study of SARS-CoV-2. Vaccines, 2023, 11, 201.	2.1	10
432	Refocus on Immunogenic Characteristics of Convalescent COVID-19 Challenged by Prototype SARS-CoV-2. Vaccines, 2023, 11, 123.	2.1	3
433	Clinical assessment of SARS-CoV-2 infectivity by rapid antigen test compared with virus isolation. Journal of Clinical Virology Plus, 2023, 3, 100133.	0.4	0
434	Therapeutic dilemmas in the management of a patient with long-term rheumatoid arthritis and severe clinical presentation of SARS-COV-2 infection. Srpski Arhiv Za Celokupno Lekarstvo, 2023, , 16-16.	0.1	0
435	Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment. PLoS ONE, 2023, 18, e0279779.	1.1	2
436	Convalescent plasma therapy in the management of COVID-19 patients and its effect on morbidity and mortality. BLDE University Journal of Health Sciences, 2023, 8, 142.	0.0	0

#	Article	IF	Citations
437	Mucosal Gene Expression in Response to SARS-CoV-2 Is Associated with Viral Load. Journal of Virology, 2023, 97, .	1.5	3
438	Impact of antibody-level on viral shedding in B.1.617.2 (Delta) variant-infected patients analyzed using a joint model of longitudinal and time-to-event data. Mathematical Biosciences and Engineering, 2023, 20, 8875-8891.	1.0	0
441	Development and comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in various African endemic settings. Diagnostic Microbiology and Infectious Disease, 2023, 105, 115903.	0.8	5
442	Assessment of Reactivity to the Administration of the mRNA Vaccine after Six Months of Observation. Vaccines, 2023, 11, 366.	2.1	1
443	Evaluation of possible COVID-19 reinfection in children: A multicenter clinical study. Archives De Pediatrie, 2023, 30, 187-191.	0.4	2
444	Label-Free SERS for Rapid Differentiation of SARS-CoV-2-Induced Serum Metabolic Profiles in Non-Hospitalized Adults. Analytical Chemistry, 2023, 95, 3638-3646.	3.2	5
445	Using SARS-CoV-2 Antibody Testing in COVID-19 Research. American Journal of Medicine, 2023, , .	0.6	0
446	SARS-CoV-2-neutralising antibody BGB-DXP593 in mild-to-moderate COVID-19: a multicentre, randomised, double-blind, phase 2 trial. EClinicalMedicine, 2023, 57, 101832.	3.2	1
447	Dynamics of SARS-CoV-2 Spike-IgG throughout Three COVID-19 Vaccination Regimens: A 21-Month Longitudinal Study of 82 Norwegian Healthcare Workers. Viruses, 2023, 15, 619.	1.5	1
448	The role of immune activation and antigen persistence in acute and long COVID. Journal of Investigative Medicine, 2023, 71, 545-562.	0.7	17
449	Clinical, Biochemical, and ATR-FTIR Spectroscopic Parameters Associated with Death or Survival in Patients with Severe COVID-19. Journal of Spectroscopy, 2023, 2023, 1-13.	0.6	4
450	SARS-CoV-2 antibody responses associate with sex, age and disease severity in previously uninfected people admitted to hospital with COVID-19: An ISARIC4C prospective study. Frontiers in Immunology, 0, 14, .	2.2	4
452	<scp>SARSâ€CoV</scp>â€2 spike protein induces endothelial dysfunction in <scp>3D</scp> engineered vascular networks. Journal of Biomedical Materials Research - Part A, 2024, 112, 524-533.	2.1	1
453	COVID-19 Microbiome Alterations. Headache, 2023, , 97-107.	0.2	0
454	Plasma cell-free DNA promise monitoring and tissue injury assessment of COVID-19. Molecular Genetics and Genomics, 2023, 298, 823-836.	1.0	2
455	An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies. AIMS Microbiology, 2023, 9, 375-401.	1.0	4
456	Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages. Nature Communications, 2023, 14, .	5.8	1